NO328559B1 - Taksanderivatkrystall og fremgangsmate for fremstilling derav, samt antitumormiddel som omfatter krystallet - Google Patents
Taksanderivatkrystall og fremgangsmate for fremstilling derav, samt antitumormiddel som omfatter krystallet Download PDFInfo
- Publication number
- NO328559B1 NO328559B1 NO20042723A NO20042723A NO328559B1 NO 328559 B1 NO328559 B1 NO 328559B1 NO 20042723 A NO20042723 A NO 20042723A NO 20042723 A NO20042723 A NO 20042723A NO 328559 B1 NO328559 B1 NO 328559B1
- Authority
- NO
- Norway
- Prior art keywords
- mixture
- crystal
- water
- crystals
- present
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 9
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000002904 solvent Substances 0.000 claims abstract description 26
- 238000002425 crystallisation Methods 0.000 claims abstract description 18
- 230000008025 crystallization Effects 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 5
- WCMBUDUPBVQEDN-VHSXEESVSA-N (2r,3s)-3-(3-fluoropyridin-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=NC=CC=C1F WCMBUDUPBVQEDN-VHSXEESVSA-N 0.000 abstract description 2
- 150000002576 ketones Chemical class 0.000 abstract description 2
- 150000002825 nitriles Chemical class 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 25
- 239000000126 substance Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000004455 differential thermal analysis Methods 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- -1 fusion drips Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001363681 | 2001-11-29 | ||
PCT/JP2002/012506 WO2003045953A1 (fr) | 2001-11-29 | 2002-11-29 | Cristaux de derive de taxane et procede de production associe |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20042723L NO20042723L (no) | 2004-06-28 |
NO328559B1 true NO328559B1 (no) | 2010-03-22 |
Family
ID=19173983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042723A NO328559B1 (no) | 2001-11-29 | 2004-06-28 | Taksanderivatkrystall og fremgangsmate for fremstilling derav, samt antitumormiddel som omfatter krystallet |
Country Status (18)
Country | Link |
---|---|
US (1) | US7410980B2 (fr) |
EP (1) | EP1457492B1 (fr) |
JP (1) | JP4310191B2 (fr) |
KR (1) | KR100886805B1 (fr) |
CN (1) | CN1295229C (fr) |
AT (1) | ATE382624T1 (fr) |
AU (1) | AU2002354126A1 (fr) |
CA (1) | CA2468953C (fr) |
DE (1) | DE60224440T2 (fr) |
DK (1) | DK1457492T3 (fr) |
ES (1) | ES2299612T3 (fr) |
HK (1) | HK1065547A1 (fr) |
MX (1) | MXPA04005192A (fr) |
NO (1) | NO328559B1 (fr) |
PT (1) | PT1457492E (fr) |
RU (1) | RU2284328C2 (fr) |
TW (1) | TWI333856B (fr) |
WO (1) | WO2003045953A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
CA2565013C (fr) * | 2004-04-30 | 2013-01-08 | Daiichi Pharmaceutical Co., Ltd. | Methode de production de taxanes pentacycliques |
US20070005911A1 (en) * | 2005-07-01 | 2007-01-04 | Nec Laboratories America, Inc. | Operating System-Based Memory Compression for Embedded Systems |
US8697892B2 (en) | 2010-06-30 | 2014-04-15 | Gfv, Llc | Taxane compounds, compositions and methods |
US8785669B2 (en) | 2010-06-30 | 2014-07-22 | Gfv, Llc | Taxane compounds, compositions and methods |
EP2447268A1 (fr) * | 2010-10-29 | 2012-05-02 | INDENA S.p.A. | Forme cristalline de la 13-[(N-tert-butoxycarbonyl)-2'-o-hexanoyl-3-phénylisosérinyl]-10-désacétylbaccatine III |
JP5909089B2 (ja) * | 2011-02-01 | 2016-04-26 | アークレイ株式会社 | 光学結晶、テラヘルツ波発生装置及び方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2219675C (fr) | 1995-04-28 | 2009-08-18 | Daiichi Pharmaceutical Co., Ltd. | Composes pentacycliques |
JP2000159757A (ja) | 1998-12-01 | 2000-06-13 | Dai Ichi Seiyaku Co Ltd | 7−デオキシタキソール誘導体の製造方法 |
ES2211550T3 (es) * | 1999-05-17 | 2004-07-16 | Bristol-Myers Squibb Company | Nuevas condiciones de reaccion para la escision de eteres de sililo en la preparacion de paclitaxel (taxol(r)) y analogos de paclitaxel. |
DK1221445T3 (da) * | 1999-10-15 | 2008-11-24 | Daiichi Sankyo Co Ltd | Pentacykliske taxanforbindelser |
US6677456B2 (en) * | 1999-10-15 | 2004-01-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic taxan compound |
JP4142444B2 (ja) | 2001-03-07 | 2008-09-03 | 第一三共株式会社 | 2−アゼチジノン誘導体の製造方法 |
-
2002
- 2002-11-29 WO PCT/JP2002/012506 patent/WO2003045953A1/fr active IP Right Grant
- 2002-11-29 AU AU2002354126A patent/AU2002354126A1/en not_active Abandoned
- 2002-11-29 KR KR1020047008200A patent/KR100886805B1/ko not_active IP Right Cessation
- 2002-11-29 DE DE60224440T patent/DE60224440T2/de not_active Expired - Lifetime
- 2002-11-29 ES ES02785977T patent/ES2299612T3/es not_active Expired - Lifetime
- 2002-11-29 CN CNB02823815XA patent/CN1295229C/zh not_active Expired - Fee Related
- 2002-11-29 CA CA2468953A patent/CA2468953C/fr not_active Expired - Lifetime
- 2002-11-29 TW TW091134817A patent/TWI333856B/zh not_active IP Right Cessation
- 2002-11-29 PT PT02785977T patent/PT1457492E/pt unknown
- 2002-11-29 US US10/495,437 patent/US7410980B2/en not_active Expired - Lifetime
- 2002-11-29 RU RU2004119547/04A patent/RU2284328C2/ru active IP Right Revival
- 2002-11-29 MX MXPA04005192A patent/MXPA04005192A/es active IP Right Grant
- 2002-11-29 DK DK02785977T patent/DK1457492T3/da active
- 2002-11-29 JP JP2003547403A patent/JP4310191B2/ja not_active Expired - Fee Related
- 2002-11-29 AT AT02785977T patent/ATE382624T1/de active
- 2002-11-29 EP EP02785977A patent/EP1457492B1/fr not_active Expired - Lifetime
-
2004
- 2004-06-28 NO NO20042723A patent/NO328559B1/no not_active IP Right Cessation
- 2004-10-28 HK HK04108450A patent/HK1065547A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200301114A (en) | 2003-07-01 |
JPWO2003045953A1 (ja) | 2005-04-07 |
EP1457492A1 (fr) | 2004-09-15 |
NO20042723L (no) | 2004-06-28 |
ES2299612T3 (es) | 2008-06-01 |
RU2004119547A (ru) | 2005-03-27 |
JP4310191B2 (ja) | 2009-08-05 |
AU2002354126A1 (en) | 2003-06-10 |
KR100886805B1 (ko) | 2009-03-05 |
KR20040081426A (ko) | 2004-09-21 |
CN1596259A (zh) | 2005-03-16 |
EP1457492A4 (fr) | 2005-03-23 |
RU2284328C2 (ru) | 2006-09-27 |
EP1457492B1 (fr) | 2008-01-02 |
CA2468953C (fr) | 2010-05-11 |
DE60224440D1 (de) | 2008-02-14 |
MXPA04005192A (es) | 2005-02-22 |
CA2468953A1 (fr) | 2003-06-05 |
PT1457492E (pt) | 2008-02-28 |
CN1295229C (zh) | 2007-01-17 |
DK1457492T3 (da) | 2008-05-13 |
US20050070579A1 (en) | 2005-03-31 |
HK1065547A1 (en) | 2005-02-25 |
DE60224440T2 (de) | 2009-01-02 |
TWI333856B (en) | 2010-12-01 |
ATE382624T1 (de) | 2008-01-15 |
US7410980B2 (en) | 2008-08-12 |
WO2003045953A1 (fr) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110099912A (zh) | 抗病毒替诺福韦脂肪族酯前药 | |
US20050026853A1 (en) | Anti-viral 7-deaza D-nucleosides and uses thereof | |
EP1014987A1 (fr) | Compositions orales de levosimendan | |
JP2003522166A (ja) | 抗腫瘍活性を有する化合物:その製法およびそれを含有する医薬組成物 | |
KR102434764B1 (ko) | 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용 | |
NO328559B1 (no) | Taksanderivatkrystall og fremgangsmate for fremstilling derav, samt antitumormiddel som omfatter krystallet | |
CN111269176A (zh) | 喹啉酮类化合物的晶型 | |
CN111269178A (zh) | 喹啉酮类化合物的晶型 | |
US4678785A (en) | Thiadiazine compounds | |
EP3453712B1 (fr) | Solvate de diéthylamine d'un inhibiteur du transporteur lié au sodium-glucose, son procédé de préparation et son application | |
NO174258B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive, krystallinske cefemsyreaddisjonssalter | |
KR100419355B1 (ko) | 무정형피레타나이드,피레타나이드다형체,이들의제조방법및이를포함하는약제학적조성물 | |
AP339A (en) | Indenoindoles compounds. | |
CN109796455B (zh) | 一种氨基吡喃衍生物的盐、其晶型及其制备方法和用途 | |
HU176145B (en) | Process for preparing derivatives of thieno/2,3-c/pyridines and of thieno/3,2-c/pyridines | |
WO2017220028A1 (fr) | Composé de médicament antiviral précurseur de nucléoside cyclo-phosphate à base de distribution du foie et son utilisation | |
JPH0211592A (ja) | 光学活性なジヒドロピリジンホスホン酸エステル | |
JPH10510547A (ja) | ピリミジンヌクレオシド誘導体 | |
US4226865A (en) | Method of treating depression | |
TWI582078B (zh) | 抑制脯氨酸羥化酶活性的化合物的晶型及其應用 | |
CN113698383A (zh) | 一种哌嗪类化合物及其应用 | |
CN114349809A (zh) | β-烟酰胺单核苷酸的晶型A及其制备方法 | |
CN112608315A (zh) | 三唑并二氮杂卓类化合物及其制备方法及医药用途 | |
CN112851640A (zh) | 嘧啶苯甲酰胺化合物的硫酸盐及其用途 | |
GB2165539A (en) | Antiviral nucleoside derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |